Summary of Study ST003954

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002477. The data can be accessed directly via it's Project DOI: 10.21228/M8G25T This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003954
Study TitleIntegrated analysis of irritable bowel syndrome comorbid with psychological disorders based on microbiomics and metabolomics
Study SummaryBackground: Irritable Bowel Syndrome (IBS), a chronic functional gastrointestinal disorder, shows high comorbidity rates with psychiatric disorders. However, comprehensive evaluations of psychiatric symptoms in IBS and their interactions with gut microbiota and metabolic disorders are lacking. This study aims to investigated mechanistic links among gut microbiota, serum amino acid metabolites, and differently psychological comorbidities. Methods: Clinical data from 267 IBS patients and 91 healthy controls (HCs) were collected using validated questionnaires: IBS Severity Scoring System (IBS-SSS), Hospital Anxiety and Depression Scale, Patient Health Questionnaire-15 (PHQ-15), Somatic Symptom Disorder-12 (SSD-12), and Symptom Checklist-90 (SCL-90). IBS patients were stratified into psychiatric comorbidity and non-comorbidity subgroups based on SCL-90 scores. Serum amino acid metabolites and gut microbiota were analyzed using LC-MS/MS targeted metabolomics and 16S rRNA gene sequencing, respectively. followed by integrative correlation analyses to explore interactions among microbiota, metabolites, and psychological comorbidities. Results: IBS patients showed significantly higher prevalence rates of all assessed psychiatric disorders compared to HCs, with somatization, anxiety, obsessive-compulsive traits, and depression as predominant manifestations. IBS patients with different psychiatric comorbidities exhibit distinct gut microbiota compositions, including altered abundances of the class Clostridia (e.g., Ruminococcus, Faecalibacterium, Monoglobus), the class Coriobacteriia (e.g., Collinsella), and the class Bacilli (e.g., Lactococcus, Erysipelatoclostridium). Metabolomic profiling revealed elevated arginine and its derivatives (Nα-acetyl-L-arginine, argininosuccinate, succinate) and reductions in aromatic amino acids (L-tryptophan, L-phenylalanine, L-tyrosine), branched-chain amino acids (L-valine, L-leucine, L-isoleucine), and neuroactive amino acids (L-glutamate, L-aspartate). Multi-omics integration implicated Clostridia and Coriobacteriia might respectively participate in the pathophysiology of somatization and anxiety comorbidities by modulating the ornithine cycle and glutamatergic metabolism. Conclusions: IBS patients exhibit multidimensional psychiatric disorders, with distinct gut microbiota and serum amino acids profiles corresponding to specific psychiatric comorbidities. The interaction between gut microbiota and amino acids may be involved in the pathogenesis of IBS with comorbid mental disorders. This study provide novel targets for early stratification and precision interventions in IBS with psychological comorbidities.
Institute
Sun Yat-sen University
Last NamePeiwei
First NameXie
AddressDepartment of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan Er Road, Guangzhou, China
Email877923714@qq.com
Phone020-87755766
Submit Date2025-06-06
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2025-06-30
Release Version1
Xie Peiwei Xie Peiwei
https://dx.doi.org/10.21228/M8G25T
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR002477
Project DOI:doi: 10.21228/M8G25T
Project Title:Integrated analysis of irritable bowel syndrome comorbid with psychological disorders based on microbiomics and metabolomics
Project Summary:Background: Irritable Bowel Syndrome (IBS), a chronic functional gastrointestinal disorder, shows high comorbidity rates with psychiatric disorders. However, comprehensive evaluations of psychiatric symptoms in IBS and their interactions with gut microbiota and metabolic disorders are lacking. This study aims to investigated mechanistic links among gut microbiota, serum amino acid metabolites, and differently psychological comorbidities. Methods: Clinical data from 267 IBS patients and 91 healthy controls (HCs) were collected using validated questionnaires: IBS Severity Scoring System (IBS-SSS), Hospital Anxiety and Depression Scale, Patient Health Questionnaire-15 (PHQ-15), Somatic Symptom Disorder-12 (SSD-12), and Symptom Checklist-90 (SCL-90). IBS patients were stratified into psychiatric comorbidity and non-comorbidity subgroups based on SCL-90 scores. Serum amino acid metabolites and gut microbiota were analyzed using LC-MS/MS targeted metabolomics and 16S rRNA gene sequencing, respectively. followed by integrative correlation analyses to explore interactions among microbiota, metabolites, and psychological comorbidities. Results: IBS patients showed significantly higher prevalence rates of all assessed psychiatric disorders compared to HCs, with somatization, anxiety, obsessive-compulsive traits, and depression as predominant manifestations. IBS patients with different psychiatric comorbidities exhibit distinct gut microbiota compositions, including altered abundances of the class Clostridia (e.g., Ruminococcus, Faecalibacterium, Monoglobus), the class Coriobacteriia (e.g., Collinsella), and the class Bacilli (e.g., Lactococcus, Erysipelatoclostridium). Metabolomic profiling revealed elevated arginine and its derivatives (Nα-acetyl-L-arginine, argininosuccinate, succinate) and reductions in aromatic amino acids (L-tryptophan, L-phenylalanine, L-tyrosine), branched-chain amino acids (L-valine, L-leucine, L-isoleucine), and neuroactive amino acids (L-glutamate, L-aspartate). Multi-omics integration implicated Clostridia and Coriobacteriia might respectively participate in the pathophysiology of somatization and anxiety comorbidities by modulating the ornithine cycle and glutamatergic metabolism. Conclusions: IBS patients exhibit multidimensional psychiatric disorders, with distinct gut microbiota and serum amino acids profiles corresponding to specific psychiatric comorbidities. The interaction between gut microbiota and amino acids may be involved in the pathogenesis of IBS with comorbid mental disorders. This study provide novel targets for early stratification and precision interventions in IBS with psychological comorbidities.
Institute:Sun Yat-sen University
Last Name:Peiwei
First Name:Xie
Address:Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan Er Road, Guangzhou, China
Email:877923714@qq.com
Phone:020-87755766

Subject:

Subject ID:SU004091
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample source Group1 Group2
SA452620A08serum HC 1
SA452621A02serum HC 1
SA452622A10serum HC 1
SA452623A09serum HC 1
SA452624A01serum HC 1
SA452625A07serum HC 1
SA452626A06serum HC 1
SA452627A03serum HC 1
SA452628A05serum HC 1
SA452629A04serum HC 1
SA452630A20serum IBS-C-10 1
SA452631A21serum IBS-C-11 1
SA452632A22serum IBS-C-12 1
SA452633A23serum IBS-C-13 1
SA452634A24serum IBS-C-14 1
SA452635A25serum IBS-C-15 1
SA452636A26serum IBS-C-16 1
SA452637A11serum IBS-C-1 1
SA452638A12serum IBS-C-2 1
SA452639A13serum IBS-C-3 1
SA452640A14serum IBS-C-4 1
SA452641A15serum IBS-C-5 1
SA452642A16serum IBS-C-6 1
SA452643A17serum IBS-C-7 1
SA452644A18serum IBS-C-8 1
SA452645A19serum IBS-C-9 1
SA452646A36serum IBS-D-10 1
SA452647A37serum IBS-D-11 1
SA452648A38serum IBS-D-12 1
SA452649A39serum IBS-D-13 1
SA452650A40serum IBS-D-14 1
SA452651A41serum IBS-D-15 1
SA452652A42serum IBS-D-16 1
SA452653A43serum IBS-D-17 1
SA452654A44serum IBS-D-18 1
SA452655A45serum IBS-D-19 1
SA452656A27serum IBS-D-1 1
SA452657A46serum IBS-D-20 1
SA452658A47serum IBS-D-21 1
SA452659A48serum IBS-D-22 1
SA452660A49serum IBS-D-23 1
SA452661A50serum IBS-D-24 1
SA452662A51serum IBS-D-25 1
SA452663A52serum IBS-D-26 1
SA452664A53serum IBS-D-27 1
SA452665A54serum IBS-D-28 1
SA452666A55serum IBS-D-29 1
SA452667A28serum IBS-D-2 1
SA452668A56serum IBS-D-30 1
SA452669A57serum IBS-D-31 1
SA452670A29serum IBS-D-3 1
SA452671A30serum IBS-D-4 1
SA452672A31serum IBS-D-5 1
SA452673A32serum IBS-D-6 1
SA452674A33serum IBS-D-7 1
SA452675A34serum IBS-D-8 1
SA452676A35serum IBS-D-9 1
SA452677A67serum IBS-M-10 1
SA452678A68serum IBS-M-11 1
SA452679A69serum IBS-M-12 1
SA452680A70serum IBS-M-13 1
SA452681A71serum IBS-M-14 1
SA452682A58serum IBS-M-1 1
SA452683A59serum IBS-M-2 1
SA452684A60serum IBS-M-3 1
SA452685A61serum IBS-M-4 1
SA452686A62serum IBS-M-5 1
SA452687A63serum IBS-M-6 1
SA452688A64serum IBS-M-7 1
SA452689A65serum IBS-M-8 1
SA452690A66serum IBS-M-9 1
Showing results 1 to 71 of 71

Collection:

Collection ID:CO004084
Collection Summary:Venous blood samples were obtained after overnight fasting, followed by serum separation through aseptic processing (centrifugation at 3,000 × g for 10 min at 4℃) and subsequent storage at -80℃.In this study, we collected serum samples from 61 IBS patients and 10 healthy controls.
Sample Type:Blood (serum)

Treatment:

Treatment ID:TR004100
Treatment Summary:Diagnosed with IBS based on the Rome IV criteria.

Sample Preparation:

Sampleprep ID:SP004097
Sampleprep Summary:Venous blood samples were obtained after overnight fasting, followed by serum separation through aseptic processing (centrifugation at 3,000 × g for 10 min at 4°C) and subsequent storage at -80°C.

Chromatography:

Chromatography ID:CH004937
Chromatography Summary:The data acquisition instrument system primarily includes Ultra Performance Liquid Chromatography (UPLC) (ExionLC™ AD, https://sciex.com.cn/) and Tandem Mass Spectrometry (MS/MS) (QTRAP® 6500+, https://sciex.com.cn/). The liquid chromatography conditions mainly comprise: 1) Chromatographic column: ACQUITY BEH Amide column (1.7 µm, 100 mm×2.1 mm i.d.); 2) Mobile phase: Phase A, ultrapure water (containing 2 mM ammonium acetate, 0.04% formic acid); Phase B, acetonitrile (containing 2 mM ammonium acetate, 0.04% formic acid); 3) Gradient elution program: 0-1.2 min A/B at 10:90 (V/V), 9 min A/B at 40:60 (V/V), 10-11 min at 60:40 (V/V), 11.01-15 min at 10:90 (V/V); 4) Flow rate 0.4 mL/min; column temperature 40°C; injection volume 2 μL. The mass spectrometry conditions mainly include: Electrospray Ionization (ESI) temperature at 550°C, mass spectrometry voltage at 5500 V in positive ion mode, and -4500 V in negative ion mode, with curtain gas (CUR) at 35 psi. In the Q-Trap 6500+, each ion pair is scanned and detected based on optimized declustering potential (DP) and collision energy (CE).
Instrument Name:SCIEX QTRAP 6500+
Column Name:ACQUITY BEH Amide (100 mm × 2.1 mm, 1.7 µm)
Column Temperature:40°C
Flow Gradient:0-1.2 minutes A/B is 10:90 (V/V), 9 minutes A/B is 40:60 (V/V), 10-11 minutes is 60:40 (V/V), 11.01-15 minutes is 10:90 (V/V)
Flow Rate:0.4 mL/min
Solvent A:100% Water; 2 mM ammonium acetate; 0.04% formic acid
Solvent B:100% Acetonitrile; 2 mM ammonium acetate; 0.04% formic acid
Chromatography Type:HILIC

Analysis:

Analysis ID:AN006499
Analysis Type:MS
Chromatography ID:CH004937
Num Factors:62
Num Metabolites:86
Rt Units:Minutes
Units:ng/ml
  
Analysis ID:AN006500
Analysis Type:MS
Chromatography ID:CH004937
Num Factors:62
Num Metabolites:8
Rt Units:Minutes
Units:ng/mL
  logo